Boron-Containing MOF Nanoparticles with Stable Metabolism in U87-MG Cells Combining Microdosimetry to Evaluate Relative Biological Effectiveness of Boron Neutron Capture Therapy.
Zhijie Wang,Runhong Lei,Zizhu Zhang,Ziteng Chen,Jiaxin Zhang,Meiru Mao,Jiacheng Li,Hongyu Tang,Mengyao Li,Xianwei Luo,Jingru Yang,Ruyu Yan,Qiuyang Liu,Linwen Lv,Kui Chen,Ya-nan Chang,Hui Yuan,Tong Liu,Jianfei Tong,Linbo Zhu,Tianjiao Liang,Weihua Zhang,Juan Li,Gengmei Xing
DOI: https://doi.org/10.1021/acsami.3c19113
2024-01-01
Abstract:Accurate prediction of the relative biological effectiveness (RBE) of boron neutron capture therapy (BNCT) is challenging. The therapy is different from other radiotherapy; the dynamic distribution of boron-containing compounds in tumor cells affects the therapeutic outcome considerably and hampers accurate measurement of the neutron-absorbed dose. Herein, we used boron-containing metal-organic framework nanoparticles (BMOFs) with high boron content to target U87-MG cells and maintain the concentration of the 10B isotope in cells. The content of boron in the cells could maintain 90% (60 ppm) within 20 min compared with that at the beginning; therefore, the accurate RBE of BNCT can be acquired. The effects of BNCT upon cells after neutron irradiation were observed, and the neutron-absorbed dose was obtained by Monte Carlo simulations. The RBE of BMOFs was 6.78, which was 4.1-fold higher than that of a small-molecule boron-containing agent (boric acid). The energy spectrum of various particles was analyzed by Monte Carlo simulations, and the RBE was verified theoretically. Our results suggested that the use of nanoparticle-based boron carriers in BNCT may have many advantages and that maintaining a stable boron distribution within cells may significantly improve the efficiency of BNCT.